PL195014B1 - Nowe, podstawione pochodne kwasu N-benzyloindol-3-iloglioksylowego o działaniu przeciwnowotworowym oraz ich zastosowanie - Google Patents
Nowe, podstawione pochodne kwasu N-benzyloindol-3-iloglioksylowego o działaniu przeciwnowotworowym oraz ich zastosowanieInfo
- Publication number
- PL195014B1 PL195014B1 PL355684A PL35568400A PL195014B1 PL 195014 B1 PL195014 B1 PL 195014B1 PL 355684 A PL355684 A PL 355684A PL 35568400 A PL35568400 A PL 35568400A PL 195014 B1 PL195014 B1 PL 195014B1
- Authority
- PL
- Poland
- Prior art keywords
- indol
- compounds
- substituted
- formula
- pyridin
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 28
- 239000002253 acid Substances 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 5
- FVSYLLUZSRCXEH-UHFFFAOYSA-N 2-[1-[(4-aminophenyl)methyl]indol-3-yl]-2-oxo-n-pyridin-4-ylacetamide Chemical compound C1=CC(N)=CC=C1CN1C2=CC=CC=C2C(C(=O)C(=O)NC=2C=CN=CC=2)=C1 FVSYLLUZSRCXEH-UHFFFAOYSA-N 0.000 claims description 9
- HRYYIVZPPROGAN-UHFFFAOYSA-N 2-[1-[(4-nitrophenyl)methyl]indol-3-yl]-2-oxo-n-pyridin-4-ylacetamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1C2=CC=CC=C2C(C(=O)C(=O)NC=2C=CN=CC=2)=C1 HRYYIVZPPROGAN-UHFFFAOYSA-N 0.000 claims description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 abstract description 6
- 239000000725 suspension Substances 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 5
- MRDIZANPJLYUKO-UHFFFAOYSA-N 2-(1-benzylindol-3-yl)-2-oxoacetic acid Chemical class C12=CC=CC=C2C(C(=O)C(=O)O)=CN1CC1=CC=CC=C1 MRDIZANPJLYUKO-UHFFFAOYSA-N 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000006071 cream Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 235000005985 organic acids Nutrition 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000000829 suppository Substances 0.000 abstract 1
- 230000001173 tumoral effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 46
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 239000000203 mixture Substances 0.000 description 19
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- -1 N-substituted indole Chemical class 0.000 description 8
- 239000000010 aprotic solvent Substances 0.000 description 8
- 238000005984 hydrogenation reaction Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000012299 nitrogen atmosphere Substances 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000007868 Raney catalyst Substances 0.000 description 4
- 229910000564 Raney nickel Inorganic materials 0.000 description 4
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 4
- 239000012454 non-polar solvent Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 description 4
- AWMLDBKLOPNOAR-UHFFFAOYSA-N 2-(1h-indol-3-yl)-2-oxoacetamide Chemical class C1=CC=C2C(C(=O)C(=O)N)=CNC2=C1 AWMLDBKLOPNOAR-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- RVPTXIBMGYNFNG-UHFFFAOYSA-N 1-[(4-nitrophenyl)methyl]indole Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1C2=CC=CC=C2C=C1 RVPTXIBMGYNFNG-UHFFFAOYSA-N 0.000 description 2
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 2
- BVRCPMXFRMVPNG-UHFFFAOYSA-N 2-(1h-indol-3-yl)-2-oxo-n-pyridin-4-ylacetamide Chemical compound C=1NC2=CC=CC=C2C=1C(=O)C(=O)NC1=CC=NC=C1 BVRCPMXFRMVPNG-UHFFFAOYSA-N 0.000 description 2
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 229960004979 fampridine Drugs 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 125000004475 heteroaralkyl group Chemical group 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- KGCNHWXDPDPSBV-UHFFFAOYSA-N p-nitrobenzyl chloride Chemical compound [O-][N+](=O)C1=CC=C(CCl)C=C1 KGCNHWXDPDPSBV-UHFFFAOYSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000003586 protic polar solvent Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- DWLVFWDCSFTDOD-UHFFFAOYSA-N 2-(1h-indol-3-yl)-2-oxoacetic acid Chemical class C1=CC=C2C(C(=O)C(=O)O)=CNC2=C1 DWLVFWDCSFTDOD-UHFFFAOYSA-N 0.000 description 1
- FPEGGKCNMYDNMW-UHFFFAOYSA-N 2-(1h-indol-3-yl)-2-oxoacetyl chloride Chemical compound C1=CC=C2C(C(=O)C(=O)Cl)=CNC2=C1 FPEGGKCNMYDNMW-UHFFFAOYSA-N 0.000 description 1
- YCWRFIYBUQBHJI-UHFFFAOYSA-N 2-(4-aminophenyl)acetonitrile Chemical group NC1=CC=C(CC#N)C=C1 YCWRFIYBUQBHJI-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
- 108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102000005473 Secretory Phospholipases A2 Human genes 0.000 description 1
- 108010031873 Secretory Phospholipases A2 Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- CBFZWGRQXZYRRR-UHFFFAOYSA-N pyridin-4-amine;hydrochloride Chemical compound Cl.NC1=CC=NC=C1 CBFZWGRQXZYRRR-UHFFFAOYSA-N 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19962300A DE19962300A1 (de) | 1999-12-23 | 1999-12-23 | Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung |
| PCT/EP2000/012947 WO2001047913A2 (de) | 1999-12-23 | 2000-12-19 | Substituierte n-benzyl-indol-3-yl- glyoxylsäure-derivate antitumorwirkung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL355684A1 PL355684A1 (en) | 2004-05-17 |
| PL195014B1 true PL195014B1 (pl) | 2007-07-31 |
Family
ID=7934006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL355684A PL195014B1 (pl) | 1999-12-23 | 2000-12-19 | Nowe, podstawione pochodne kwasu N-benzyloindol-3-iloglioksylowego o działaniu przeciwnowotworowym oraz ich zastosowanie |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6432987B2 (cs) |
| EP (1) | EP1240157B1 (cs) |
| JP (1) | JP2003519137A (cs) |
| KR (1) | KR100747425B1 (cs) |
| CN (1) | CN1283637C (cs) |
| AR (1) | AR027098A1 (cs) |
| AT (1) | ATE259364T1 (cs) |
| AU (1) | AU772745B2 (cs) |
| BG (1) | BG106924A (cs) |
| BR (1) | BR0016712A (cs) |
| CA (1) | CA2395259A1 (cs) |
| CO (1) | CO5251472A1 (cs) |
| CZ (1) | CZ20022094A3 (cs) |
| DE (2) | DE19962300A1 (cs) |
| DK (1) | DK1240157T3 (cs) |
| ES (1) | ES2215768T3 (cs) |
| HK (1) | HK1054038B (cs) |
| HU (1) | HUP0203716A3 (cs) |
| IL (1) | IL150235A0 (cs) |
| MX (1) | MXPA02006229A (cs) |
| NO (1) | NO324750B1 (cs) |
| NZ (2) | NZ519977A (cs) |
| PL (1) | PL195014B1 (cs) |
| PT (1) | PT1240157E (cs) |
| RU (1) | RU2266280C2 (cs) |
| SK (1) | SK8752002A3 (cs) |
| TR (1) | TR200400601T4 (cs) |
| TW (1) | TWI284128B (cs) |
| UA (1) | UA75060C2 (cs) |
| WO (1) | WO2001047913A2 (cs) |
| ZA (1) | ZA200204896B (cs) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19946301A1 (de) * | 1998-04-02 | 2001-04-19 | Asta Medica Ag | Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften |
| DE19814838C2 (de) * | 1998-04-02 | 2001-01-18 | Asta Medica Ag | Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung |
| DE10037310A1 (de) * | 2000-07-28 | 2002-02-07 | Asta Medica Ag | Neue Indolderivate und deren Verwendung als Arzneimittel |
| DE10318611A1 (de) * | 2003-04-24 | 2004-11-11 | Elbion Ag | 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika |
| DE10318609A1 (de) * | 2003-04-24 | 2004-11-11 | Elbion Ag | 5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika |
| RU2327696C2 (ru) * | 2003-06-05 | 2008-06-27 | Центарис Гмбх | Производные индола, обладающие индуцирующим апоптоз эффектом (варианты), фармацевтическая композиция на их основе |
| US7211588B2 (en) * | 2003-07-25 | 2007-05-01 | Zentaris Gmbh | N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation |
| MXPA06002853A (es) | 2003-09-11 | 2006-06-14 | Kemia Inc | Inhibidores citoquina. |
| US7268159B2 (en) * | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
| DE102004031538A1 (de) * | 2004-06-29 | 2006-02-09 | Baxter International Inc., Deerfield | Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit |
| CN101443006B (zh) | 2004-12-31 | 2012-10-10 | 雷迪美国治疗股份有限公司 | 作为cetp抑制剂的新颖的苄胺衍生物 |
| US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| EP2363128B1 (en) * | 2005-03-11 | 2016-02-17 | Vertex Pharmaceuticals Incorporated | Indole modulators of ATP-binding cassette transporters |
| EA018724B1 (ru) * | 2006-08-07 | 2013-10-30 | Айронвуд Фармасьютикалз, Инк. | Соединения индола |
| AU2007325797B2 (en) * | 2006-11-28 | 2014-03-13 | Ziopharm Oncology, Inc. | Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer |
| AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
| AR084433A1 (es) | 2010-12-22 | 2013-05-15 | Ironwood Pharmaceuticals Inc | Inhibidores de la faah y composiciones farmaceuticas que los contienen |
| CA2845284C (en) | 2011-08-18 | 2018-03-06 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors |
| CN103958511A (zh) | 2011-09-27 | 2014-07-30 | 雷迪博士实验室有限公司 | 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1028812A (en) * | 1962-08-28 | 1966-05-11 | Ici Ltd | Indole derivatives |
| KR950701317A (ko) * | 1992-05-08 | 1995-03-23 | 오오쓰까 아끼히꼬 | 인돌 유도체(Indole Derivative) |
| IL109311A0 (en) * | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
| ES2122555T3 (es) * | 1994-02-22 | 1998-12-16 | Merrell Pharma Inc | Nuevos derivados indolicos utiles para tratar neoplasmas y trastornos relacionados con estrogenos. |
| DK0675110T3 (da) * | 1994-04-01 | 2002-10-07 | Lilly Co Eli | 1H-indol-3-glyoxylamid-sPLA2-inhibitorer |
| DE19636150A1 (de) * | 1996-09-06 | 1998-03-12 | Asta Medica Ag | N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung |
| CA2279211A1 (en) * | 1997-02-20 | 1998-08-27 | Shionogi & Co., Ltd. | Indole dicarboxylic acid derivatives |
| US5972988A (en) * | 1997-03-26 | 1999-10-26 | Eli Lilly And Company | Method for treatment of chronic bronchitis using indole compounds |
| WO1998047507A1 (en) * | 1997-04-24 | 1998-10-29 | Shionogi & Co., Ltd. | Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds |
| TW455581B (en) * | 1997-06-26 | 2001-09-21 | Lilly Co Eli | Process for preparing 4-substituted-1H-indole-3-glyoxamides |
| CA2301586A1 (en) * | 1997-08-28 | 1999-03-04 | William Louis Macias | Method for treatment of non-rheumatoid arthritis |
| CA2304482A1 (en) * | 1997-09-26 | 1999-04-08 | Eli Lilly And Company | Method for the treatment of cystic fibrosis |
| AU1200799A (en) * | 1997-10-27 | 1999-05-17 | Eli Lilly And Company | Isopropyl ester prodrugs of indole spla2 inhibitors |
| WO1999021559A1 (en) * | 1997-10-27 | 1999-05-06 | Eli Lilly And Company | MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS |
| JP2001520991A (ja) * | 1997-10-27 | 2001-11-06 | イーライ・リリー・アンド・カンパニー | インドールｓＰＬＡ２阻害剤のＮ，Ｎ−ジエチルグリコールアミドエステルプロドラッグ |
| WO1999024033A1 (en) * | 1997-11-12 | 1999-05-20 | Shionogi & Co., Ltd. | Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds |
| CA2310249A1 (en) * | 1997-11-14 | 1999-05-27 | August Masaru Watanabe | Treatment for alzheimer's disease |
| BR9908275A (pt) * | 1998-02-25 | 2000-10-24 | Genetics Inst | Inibidores de enzimas fosfolipase |
| DE19814838C2 (de) * | 1998-04-02 | 2001-01-18 | Asta Medica Ag | Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung |
| DZ2770A1 (fr) * | 1998-04-17 | 2003-12-01 | Lilly Co Eli | Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4. |
| ES2262072T3 (es) * | 1998-04-28 | 2006-11-16 | Elbion Ag | Derivados de indol y su utilizacion como inhibidores de la fosfodiesterasa 4. |
| DE19818964A1 (de) * | 1998-04-28 | 1999-11-04 | Dresden Arzneimittel | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung |
| SK16342000A3 (sk) * | 1998-05-01 | 2002-04-04 | Eli Lilly And Company | Liečivo na liečbu zápalového ochorenia čreva obsahujúce 1H-indol-3-glyoxylamidy |
| WO1999056752A1 (en) * | 1998-05-01 | 1999-11-11 | Eli Lilly And Company | sPLA2 INHIBITOR ESTER |
| WO2000067802A1 (en) * | 1999-05-10 | 2000-11-16 | Protarga, Inc. | Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof |
| TWI269654B (en) * | 1999-09-28 | 2007-01-01 | Baxter Healthcare Sa | N-substituted indole-3-glyoxylamide compounds having anti-tumor action |
-
1999
- 1999-12-23 DE DE19962300A patent/DE19962300A1/de not_active Withdrawn
-
2000
- 2000-12-15 US US09/736,431 patent/US6432987B2/en not_active Expired - Fee Related
- 2000-12-19 AT AT00983349T patent/ATE259364T1/de not_active IP Right Cessation
- 2000-12-19 CN CNB008182094A patent/CN1283637C/zh not_active Expired - Fee Related
- 2000-12-19 DE DE50005284T patent/DE50005284D1/de not_active Expired - Fee Related
- 2000-12-19 CA CA002395259A patent/CA2395259A1/en not_active Abandoned
- 2000-12-19 IL IL15023500A patent/IL150235A0/xx not_active IP Right Cessation
- 2000-12-19 EP EP00983349A patent/EP1240157B1/de not_active Expired - Lifetime
- 2000-12-19 MX MXPA02006229A patent/MXPA02006229A/es active IP Right Grant
- 2000-12-19 TR TR2004/00601T patent/TR200400601T4/xx unknown
- 2000-12-19 RU RU2002120462/04A patent/RU2266280C2/ru not_active IP Right Cessation
- 2000-12-19 WO PCT/EP2000/012947 patent/WO2001047913A2/de not_active Ceased
- 2000-12-19 KR KR1020027007933A patent/KR100747425B1/ko not_active Expired - Fee Related
- 2000-12-19 ES ES00983349T patent/ES2215768T3/es not_active Expired - Lifetime
- 2000-12-19 NZ NZ519977A patent/NZ519977A/en unknown
- 2000-12-19 DK DK00983349T patent/DK1240157T3/da active
- 2000-12-19 JP JP2001549383A patent/JP2003519137A/ja not_active Withdrawn
- 2000-12-19 PT PT00983349T patent/PT1240157E/pt unknown
- 2000-12-19 HU HU0203716A patent/HUP0203716A3/hu unknown
- 2000-12-19 TW TW089127265A patent/TWI284128B/zh not_active IP Right Cessation
- 2000-12-19 NZ NZ533731A patent/NZ533731A/en unknown
- 2000-12-19 PL PL355684A patent/PL195014B1/pl unknown
- 2000-12-19 HK HK03106408.0A patent/HK1054038B/zh not_active IP Right Cessation
- 2000-12-19 SK SK875-2002A patent/SK8752002A3/sk unknown
- 2000-12-19 UA UA2002076107A patent/UA75060C2/uk unknown
- 2000-12-19 AU AU20119/01A patent/AU772745B2/en not_active Ceased
- 2000-12-19 CZ CZ20022094A patent/CZ20022094A3/cs unknown
- 2000-12-19 BR BR0016712-6A patent/BR0016712A/pt not_active Application Discontinuation
- 2000-12-22 CO CO00097375A patent/CO5251472A1/es not_active Application Discontinuation
- 2000-12-22 AR ARP000106916A patent/AR027098A1/es not_active Application Discontinuation
-
2002
- 2002-06-19 ZA ZA200204896A patent/ZA200204896B/en unknown
- 2002-06-21 NO NO20023039A patent/NO324750B1/no unknown
- 2002-07-16 BG BG106924A patent/BG106924A/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL195014B1 (pl) | Nowe, podstawione pochodne kwasu N-benzyloindol-3-iloglioksylowego o działaniu przeciwnowotworowym oraz ich zastosowanie | |
| US5618818A (en) | Muscarinic agonist compounds | |
| JP5253696B2 (ja) | 抗腫瘍作用を有するインドリル−３−グリオキシル酸誘導体 | |
| CA2215013C (en) | N-substituted indol-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action | |
| HU220592B1 (hu) | Eljárás diaminszármazékok és ezeket hatóanyagként tartalmazó gyógyszerkészítmények előállítására | |
| US7125906B2 (en) | Indole derivatives having anti-angiogenetic activity | |
| JPH01313469A (ja) | キナゾリン、その製法及びこれを含有する抗腫瘍作用を有する製薬学的組成物 | |
| WO1992001681A1 (en) | Benzopyran derivative, production thereof, and pharmaceutical composition containing the same | |
| RS59300B1 (sr) | Postupak za tretman hepatičke encefalopatije | |
| HUT61002A (en) | Process for producing 2-aminopyrimdine-4-carboxamide derivatives and pharmaceutical compositions comprising such compounds | |
| HUT70557A (en) | N,n'-disubstituted amine derivative, pharmaceutical compositions containing them and process for producing the compounds and the compositions | |
| JP2008523028A (ja) | ドーパミン−ｄ２受容体に関する親和力およびセロトニン再吸収部位の組み合わせを有するベンズジオキサンピペラジン誘導体 | |
| CN102617465A (zh) | 他克林-咖啡酸杂联体,其制备方法及其药物组合物 | |
| HUT72439A (en) | Benzo[f]quinoxalindione derivatives, their preparation and their use in drugs | |
| US5424464A (en) | p-[Bis(2-chloroethyl)amino]phenylalanine compounds | |
| KR20010082703A (ko) | 6-술파모일-3-퀴놀릴포스폰산 화합물, 이의 제조 방법 및이를 함유하는 약제 조성물 | |
| CZ302588B6 (cs) | Použití N-substituovaného indol-3-glyoxylamidu pro výrobu léciva | |
| JPS6332787B2 (cs) | ||
| JP2004511547A (ja) | 尿失禁治療用の新規ｍ−アミノ−フェニルイミノ−イミダゾリジン誘導体 | |
| MXPA00009646A (en) | Indolyl-3-glyoxylic acid derivatives with antitumoral activity |